Bard Picks Up Device Maker Lutonix For $325M

Law360, New York (December 20, 2011, 9:12 PM EST) -- New Jersey-based C.R. Bard Inc. will acquire fellow medical device company Lutonix Inc. for as much as $325 million to tap into an arterial disease treatment Lutonix has been developing, Bard announced Tuesday.

Bard said it would pay $225 million for Minneapolis-based Lutonix at the merger's closing and put forward an additional $100 million if the company's drug-coated balloon technology receives premarket approval from the U.S. Food and Drug Administration.

Lutonix is conducting the first and only FDA-approved investigational device exemption trial using drug-coated balloons for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.